drugset / Trial / NCT00455923

SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

NCT00455923

Phase 4 Completed 100 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

An 18 months randomised double-blind study with two parallel arms with start dose of inhaled SERETIDE 50/100mcg BD or FLIXOTIDE 100mcg BD, Phase I is 6 months where the patient will be up-titrated until well controlled is achieved, After 6 months the treatment continues without changes during 9 months = PhaseII. The aim is to investigate and evaluate the assumption that the combination therapy with SERETIDE controls mild persistent asthma better than inhaled corticosteroids(FLIXOTIDE) alone.

Timeline

Start
2005-05-03
Primary completion
2007-07-31
Completion
2007-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 100 ug Inhaled
Subject Fluticasone propionate Other / unclassified 250 ug Inhaled
Subject Fluticasone propionate Other / unclassified 500 ug Inhaled
Subject Sal Unknown 50 ug Inhaled

Indications